Background. Pediatric and young adult central nervous system (CNS) germinomas have favorable cure rates. However, long-term follow-up data are limited because of the rarity of this tumor. We report the long-term overall survival (OS) and causes of late mortality for these patients.
Germ cell tumors (GCTs) are broadly classified as gonadal and extragonadal. Extragonadal GCTs comprise 5% of all GCTs. 1 It is hypothesized that these tumors either develop from abnormal migration of primordial germ cells, which originate in the embryonic yolk sac and migrate to the gonads during fetal development, or from misdirected pluripotent embryonic cells. 2 The CNS is one of the most common sites of extragonadal GCTs. 3, 4 Approximately half of the CNS GCTs occur in the pineal gland. The incidence of CNS GCTs is rare at 0.1 per 100 000 personyears in the United States, and they represent 3%-5% of CNS tumors in the pediatric population. 5 Males are more commonly affected than females, with an incidence ratio of 3:1. 2 There are 2 broad histological categories of CNS GCTs: germinomatous and nongerminomatous. Germinomatous GCTs (GGCTs) are histologically analogous to seminoma of the testes and dysgerminoma of the ovaries. Nongerminomatous GCTs (NGGCTs) comprise a heterogeneous group of tumors that include embryonal carcinoma, choriocarcinoma, teratoma, and mixed germ cell tumor. Histology serves as an important prognostic factor. The 5-year overall survival (OS) for GGCTs is .90%. NGGCTs have 5-year OS ranging widely from 8% to 94% with an average of 75%. 6, 7 However, regardless of histology, the intent of treatment is cure, as these tumors are very sensitive to radiation and chemotherapy.
Radiation plays a central role in the treatment paradigm for this disease and can be associated with late treatment-related toxicities such as secondary neoplasms, endocrine deficiencies, and stroke. Historically, all of these tumors were treated with craniospinal radiation; however, the current standard of care for localized GGCTs is whole ventricular radiation with a boost to the primary. Craniospinal radiation continues to be a part of treatment for those who have disseminated disease and those with NGGCTs. A current Children's Oncology Group (COG) trial is examining the efficacy of reducing the radiation dose in patients with GGCTs who have complete response to chemotherapy because neoadjuvant chemotherapy has shown promising results in phase II trials. 8 -10 Chemotherapy alone, however, has been shown to result in inferior survival outcomes, and therefore radiation remains the cornerstone of curative therapy.
11
Given the favorable prognosis of GCTs compared with other pediatric CNS tumors, long-term treatment-related toxicities are especially relevant. The Childhood Cancer Survivor Study (CCSS), which characterized the mortality experience of 20 483 survivors, shows that with increasing years of follow-up, there is an increase in mortality attributable to treatment-related causes (eg, secondary neoplasms, cardiac death, pulmonary death, and infection) and a decrease in mortality attributable to primary cancer or recurrence. 12, 13 A Surveillance, Epidemiology, and End Results (SEER)-based analysis of mortality in 5-year survivors of pediatric CNS tumors also showed that survivors are at an increased risk for death due to cardiovascular disease, cerebrovascular disease, and secondary neoplasms.
14 However, data specifically related to late effects in CNS GCT survivors are very limited. To our knowledge, there have not been any analyses of late causes of mortality in pediatric and young adult CNS GCTs. Our goal was to assess the causes of mortality and late effects in 5-year survivors of pediatric and young adult CNS GCTs.
Materials and Methods
The United States SEER database was utilized to conduct this study. Data were queried from the November 2012 submission of all 18 registries. Inclusion criteria included age at diagnosis of 0 -30 years, diagnosis of CNS GGCT or NGGCT, and survival of at least 5 years after initial diagnosis. Those who had a prior diagnosis of cancer were excluded. Patients had been diagnosed between 1973 and 2005. CNS GGCTs were identified using the histological type ICD-O-3 9064, and CNS NGGCTs were identified using the histological types ICD-O-3 9080, 9085, 9101, 9100, 9065, 9070, 9082, and 9071.
Patient demographic information was collected and included age, race, sex, and year of diagnosis. Cause of death is a classification in the SEER database and was categorized as either death from recurrent disease, second malignancy, cerebrovascular disease, other, or unknown. Information regarding the development of subsequent malignant neoplasm (SMN) was obtained. The latency period to the development of a SMN was calculated as the time between initial brain tumor diagnosis and diagnosis of a second tumor.
Statistical Analysis
The Kaplan-Meier method was used to calculate OS. Survival curves were compared using the log-rank test. Expected survival rate was obtained by matching the study cohort to the United States population by age, race, sex, and date of diagnosis as generated by SEER*Stat statistical software. The ratio of observed deaths to expected deaths was used to calculate standardized mortality ratios (SMRs). Expected deaths were calculated using age-and sex-specific rates of mortality in the United States (obtained from the National Center for Health Statistics). SMR for overall mortality included all causes of death. Cause-specific SMRs were also calculated for cerebrovascular disease and death from cancer. Cumulative incidence was calculated using a competing risk model. Wilcoxon rank-sum tests and Fisher' exact tests were used to assess statistical significance of associations between study groups. Univariate Cox regression was utilized to identify risk factors pertaining to survival. Stata 10SE was used to complete statistical analyses.
Results

Patient Characteristics
From 1973 to 2005, a total of 499 patients met our inclusion criteria and were included for analysis. The cohort consisted of 405 (81.2%) patients with GGCTs and 94 (18.8%) patients with NGGCTs. Diagnosis was established via positive histology or cytology in 91% and 93% of patients, respectively. Radiography without microscopic confirmation was utilized in 7.2% of GGCTs and 3.2% of NGGCTs, and laboratory values alone were used in 1.2% of GGCTs and 4.3% of NGGCTs.
The NGGCTs were categorized as follows: 53.2% mixed germ cell tumors, 29.8% benign teratomas, 5.3% yolk sac tumors, 5.3% pure choriocarcinomas, 3.2% embryonal carcinomas, 1.1% malignant teratomas, and 2.1% unknown. Median age at diagnosis was 12.5 years (range, 0 -27 years). Median follow-up time was 10.8 years (range, 5 -32 years), providing 698 person-years of follow-up. The male-to-female ratio was 3.3:1. Eighty-three percent of patients were white, 5.3% were black, and 11.7% were classified as other (eg, American Indian/Alaska native, Asian/Pacific Islander) ( Table 1) .
For patients with GGCTs, median follow-up time was 9.9 years (range, 5.0 -37.8 years), providing 3 103 person-years of follow-up. The male-to-female sex ratio was 3.6: 1. The racial 
Treatment Characteristics
For GGCTs, radiation was part of the initial treatment in 86.4% of patients and was combined with surgery in 38.3% of patients. It was unknown whether radiation was administered in 1.9% of patients. There was a decreasing use of radiation as part of initial therapy with more recent diagnoses (Wilcoxon rank-sum, P ¼ .013). When comparing surgery and radiation (n ¼ 155) with radiation alone (n ¼ 195), there was no difference in OS (log-rank, P ¼ .639). Survival also did not differ when comparing patients who underwent surgery with those who did not (log-rank, P ¼ .395). Radiation was part of the initial treatment in 62.8% of patients with NGGCTs and was combined with surgery in 48.9% of patients. Unlike GGCTs, the use of radiation has not changed over time (Wilcoxon rank-sum, P ¼ .928).
Survival Analysis
Among the 405 GGCT survivors, 46 (11%) were dead at the time of last follow-up. Median survival was 35 years (range, 5.0 -37.7 years). The OS was 92.3% at 10 years of follow-up, 84.1% at 20 years of follow-up, and 61.9% at 30 years of follow-up (Fig. 1 ). This is a much lower OS than the expected survival for a cohort of this age and sex (Fig. 1) . Male sex did not predict for worsened OS (log-rank, P ¼ .328), and there were no survival differences when comparing pineal with nonpineal locations (log-rank, P ¼ .592). When stratifying OS of all GCTs by decade of diagnosis, OS did not improve with more recent treatments (Fig. 2) 
Cause-specific Mortality
At 25 years, the cumulative incidence of death due to cancer for all GCTs (either SMN or primary recurrence) was 16% (95% CI, 9.3 -24.3) (Fig. 3) . Of the 46 GGCT deaths, 23 (50%) were due to a brain tumor. Twenty-two of the 23 (95.6%) brain-tumor deaths were coded as recurrent disease, and 1 (4.3%) was coded as a CNS SMN. One death (2.2%) was due to non-CNS SMN (sarcoma). Median time from diagnosis to cancer-related death was 9.5 years (range, 5.1 -26.5 years). After excluding those who developed SMN, median time to GGCT-specific cancer death was 9.1 years (range, 5.1 -26.5 years). The most common noncancer cause of death was stroke, representing 8.7% of all deaths. Survivors of GGCT experienced a nearly 59-fold increase in risk of death from stroke (SMR, 58.93; 95% CI, 18.70-142.10). Four patients died from stoke at ages 20, 37, 38, and 44 years, and the median time to death from stroke was 23.8 years (range, 10.1-30.2 years). Three of these deaths occurred in patients who were diagnosed prior to the age of 20 years, and these survivors experienced a 100-fold increase in risk of death from stroke (SMR, 100; 95% CI, 20.0 -292.20). Fourteen (30.4%) of the patients died of other noncancerrelated causes such as accidents/adverse events, cardiovascular disease, and chronic obstructive pulmonary disease. The cause of death was unknown in 8.7% of the patients.
Of the 8 NGGCT deaths, 5 (62.5%) were attributable to brain tumor, and all 5 were coded as recurrent disease. Of the 3 remaining deaths, the causes were sepsis, accident/adverse event, and unknown cause. Median time to cancer-related death was 7.1 years (range, 5.4 -15.5 years).
Subsequent Malignant Neoplasms
For the entire cohort, the cumulative incidence of SMN at 25 years was 6.0% (95% CI, 2.50 -11.80) (Fig. 4) . For GGCT survivors, cumulative incidence of SMN at 25 years was 6.1% (95% CI, 2.2-12.5). There were 8 SMNs: 1 malignant meningioma, 3 sarcomas, 1 acute lymphocytic leukemia, 1 esophageal cancer, 1 parotid malignancy, and 1 glioblastoma. The median time between first and second malignancy was 15 years. Sarcoma had the shortest time to SMN, and esophageal cancer had the longest time to SMN with a latency period of 5.2 years and 30.1 years, respectively. There was one patient with a third malignancy (acute myeloid leukemia), which occurred 11.5 years after the first malignancy and 1.9 years after the second.
For NGGCT survivors, cumulative incidence of SMN at 25 years was 4.1% (95% CI, 1.10 -10.40). There were 4 SMNs: 2 melanomas, 1 testicular malignancy, and 1 mediastinal nonseminomatous germ cell tumor (NSGCT). The median time 
Discussion
Although our study adds to the growing literature on late causes of mortality, it is unique because it provides deeper insight into the causes of death and the mortality risks specific to CNS GCTs, which are rare pediatric tumors in the United States. There have been multiple SEER-based analyses on CNS GCTs; however, these have largely been descriptive, reporting frequencies, incidences, and survival rates stratified by age, sex, race, and intracranial location. 3, 4, 15 To our knowledge, this is the first study to examine causes of late mortality and late effects for CNS GCT in a large population-based cancer registry.
We highlight the increased risk of mortality in 5-year survivors of CNS GGCTs and NGGCTs. Although the cure rate for these tumors is relatively high compared with those of other pediatric CNS tumors, survivors experience a 10-fold increase in mortality risk compared with their peers. This increased risk of mortality appears to be largely due to recurrent disease 5 years after diagnosis. The SEER database does not provide information on whether recurrences were biopsy proven. Therefore, theoretically, some of the patients coded as dying from CNS recurrences could have had second CNS malignancies that were not captured.
While it is very possible that the number of secondary brain tumors is underestimated, death due to late recurrence after 5 years appears to play a major role in OS. Existing literature suggests that 65% -80% of GGCT relapses occur within the first 5 years; however, there have been several reports of relapses occurring 10 years or more after initial diagnosis. 16 -19 Alapetite et al analyzed the patterns of relapses in patients who were treated on the prospective Société Française d'Oncologie Pédia-trique (SFOP) TGM-TC-90 protocol. With a median follow-up of 10 years (range, 1 -16 years), they found that the latest relapse occurred at 10 years and emphasized the need for caution when interpreting early reports of prospective data with shortterm follow-up. 20 These data also highlight the risk of SMNs and their adverse effect on OS. Cumulative incidence of SMN at 25 years was 6.1% for GGCTs and 4.1% for NGGCTs, which is comparable to previously reported cumulative incidence of 6.4% at 30 years for pediatric CNS malignancies.
14 In our cohort, deaths due SMN or recurrent disease accounted for 29 of 54 deaths (54%).
Our results are consistent with prior studies showing that cancer remains an important late cause of death in pediatric survivors. When analyzing the late causes of death in 5-year survivors of pediatric CNS malignancies, Perkins et al found that 50% of the deaths were attributable to recurrent disease. 14 The CCSS demonstrated that the annual risk of death from recurrence or progression of primary was 0.44% per year, but this varied across diagnostic groups with the highest rates being in Ewing's sarcoma (0.95% per year) and CNS tumors (1.14% per year for medulloblastoma and 0.95% per year for other CNS tumors). 12 Nordic data from populationbased registries assessed cause of death in 37 515 five-year survivors of childhood and adolescent cancer and categorized them as follows: death due to the first cancer, death due to a second or subsequent primary cancer, or death due to a noncancer-related cause. For CNS tumors, 65.8% of deaths were attributable to recurrence or progression of primary disease, 6.5% were attributable to second cancers, and 27.7% were attributable to noncancer-related causes. 21 An older British study analyzed 9 080 five-year survivors of childhood cancer diagnosed between 1971 and 1985 and found that death was attributed to recurrent tumor in 74% of cases, treatment-related effect in 15% of cases, second primary tumor in 7% of cases, and other causes in 4% of cases. 22 In addition to death from cancer, survivors of GGCTs experience a nearly 59-fold increase in risk of death from stroke compared with age-and sex-matched peers. The increased risk of death from stroke is even more striking when analyzing those diagnosed prior to the age of 20 years (SMR, 100; 95% CI, 20.0-292.20). Although radiation at initial therapy was not associated with stroke, radiation in the recurrent disease setting was not captured in SEER. Therefore, the utilization of radiation may be underestimated. There are multiple retrospective reviews associating childhood cranial radiation with increased risk of stroke. 23, 24 CCSS estimated that the age-adjusted stroke rate per 1 000 000 person-years was 77 (95% CI, 62-96) in survivors of childhood cranial radiation therapy compared with 9.3 (95% CI, 4 -23) in siblings. 24 Stroke risk also varied according to radiation dose, presence of hypertension, and race.
It is important to recognize the limitations of utilizing SEER data. Although the SEER registry represents 28% of the US population, the following treatment information is not coded: utilization of chemotherapy, outcome of surgery, radiation dose, and radiation volume. Therefore, one cannot correlate late effects with particular radiation doses/volumes or administration of particular chemotherapies. Not all coded recurrences are biopsy proven. Therefore, theoretically, some patients who were coded as dying from recurrence may have died from a SMN. This could potentially underestimate the cumulative incidence of SMNs. Finally, treatment-specific morbidities (eg, hypopituitarism, neurocognitive deficits, or developmental delays) related to treatment are not captured in SEER. Despite these limitations, the SEER database has many strengths including robust follow-up data, which is critical to cause-of-death analysis. Follow-up in the SEER database is maintained by both active and passive methods, and the follow-up rate into 2011 for the standard 9 registries is 92.55% for those aged 0 -19 years. 25 Although pediatric and young adult CNS GCTs have favorable cure rates, late recurrences, subsequent malignancies, and stroke have a significant impact on long-term survival. The majority of deaths are cancer related, either representing late recurrences or SMNs. Long-term follow-up for CNS GCT patients is recommended, given their risks for late recurrence and SMN. Assessment of stroke risk factors should be considered in the standard follow-up routine for these patients.
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